PIK3CB and breast cancer: Some of the pan-PI3K inhibitors include XL147 [44] and GDC-0941 [45], although the most advanced in clinical research in HR-positive breast cancer is the pan-PI3K inhibitor BKM120 (buparlisib) [46] (Table 1).